A phase 2 clinical trial of preoperative pembrolizumab and chemotherapy followed by adjuvant pembrolizumab in resectable locoregionally recurrent head and neck squamous cell carcinoma. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results